C. Michael Neuwelt - Concepedia

Concepedia

Author

C. Michael Neuwelt

Stanford University

Also Known As

C M Neuwelt, C M. Neuwelt, C Michael Neuwelt, C. M. Neuwelt, C. Michael Neuwelt, C.M Neuwelt, Clark M. Neuwelt, Neuwelt, C M

22

Publications

3.2K

Citations

16

H-Index

48

Concepts

All Affiliations

Stanford University Cedars-Sinai Medical Center Alameda Health System Johns Hopkins University University of California San Diego

CM

About

C. Michael Neuwelt is an author at Stanford University specializing in medicine, autoimmune disease, and rheumatoid arthritis.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	7	7	1.1K
2	Immunology	4	4	496
3	Health Sciences	1	1	79
4	Allergy	1	1	86
5	Epidemiology	1	1	18

C. Michael Neuwelt

×

16

Publications

3.2K

Citations

16

H-Index

	Year	Citations
Efficacy and safety of rituximab in moderately‐to‐severely active systemic lupus erythematosus: The randomized, double‐blind, phase ii/iii systemic lupus erythematosus evaluation of rituximab trial Joan T. Merrill, C. Michael Neuwelt, Daniel J. Wallace, Arthritis & Rheumatism	2009	1.3K
Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial Peter Nash, Bruce Kirkham, Masato Okada, The Lancet Rheumatoid DisorderRheumatologySpirit-p2 Phase 3Autoimmune DiseaseMedicine	2017	390
Genome-Wide Screen for Systemic Lupus Erythematosus Susceptibility Genes in Multiplex Families Ruty Mehrian‐Shai, Francisco P. Quismorio, Lin Li, Human Molecular Genetics GeneticsImmunologyGenetic EpidemiologyLinkage AnalysisDisease Gene Identification	1999	313
Sifalimumab, a Human Anti–Interferon‐α Monoclonal Antibody, in Systemic Lupus Erythematosus: A Phase I Randomized, Controlled, Dose‐Escalation Study Michelle Petri, Daniel J. Wallace, Alberto Spindler, Arthritis & Rheumatism	2013	238
Efficacy and Safety of Epratuzumab in Moderately to Severely Active Systemic Lupus Erythematosus: Results From Two Phase III Randomized, Double‐Blind, Placebo‐Controlled Trials Megan E. B. Clowse, Daniel J. Wallace, Richard Furie, Arthritis & Rheumatology	2016	223
Role of intravenous cyclophosphamide in the treatment of severe neuropsychiatric systemic lupus erythematosus C. Michael Neuwelt, S Lacks, Brian R. Kaye, The American Journal of Medicine Autoimmune DiseaseSystemic Lupus Erythematosus TreatmentMedicineLupusSystemic Treatment	1995	171
Participatory patient–physician communication and morbidity in patients with systemic lupus erythematosus Michael M. Ward, Saigeetha Sundaramurthy, Debra Lotstein, Arthritis Care & Research	2003	118
The Role of Plasmapheresis in the Treatment of Severe Central Nervous System Neuropsychiatric Systemic Lupus Erythematosus C. Michael Neuwelt Therapeutic Apheresis and Dialysis ImmunologyImmunotherapyRheumatoid DisorderClinical TrialsInflammatory Rheumatic Disease	2003	86
Catastrophic antiphospholipid syndrome. Response to repeated plasmapheresis over three years C. Michael Neuwelt, David Daikh, John A. Linfoot, Arthritis & Rheumatism ImmunologyPathologyThrombosisCatastrophic Antiphospholipid SyndromeHematology	1997	79
Psychosocial correlates of morbidity in women with systemic lupus erythematosus. Michael M. Ward, Debra Lotstein, Terry Bush, PubMed	1999	52

Page 1